雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Efficacy and safety of twice-daily biphasic insulin aspart 30 ; switching from biphasic human insulin(40R,50R) Keyword: ①2型糖尿病 , ②インスリン療法 , ③二相性インスリンアナログ製剤 , ④ヒトインスリン混合製剤 , ⑤食直前投与 pp.631-635
Published Date 2006/7/15
DOI https://doi.org/10.11477/mf.1415100268
  • Abstract
  • Look Inside
  • Reference

 To evaluate the efficacy and safety of biphasic insulin aspart 30(NovoRapid(R) 30 Mix),we conducted an open-labeled clinical study using biphasic insulin aspart 30 for 24 weeks of treatment in 8 Type 2 diabetic patients who had been treated with biphasic human insulin 40R or 50R. As a control group,patients who had been treated with biphasic human insulin 30R and switched to biphasic insulin aspart 30 were also observed. The changes in HbA1C,casual blood glucose,body weight,insulin dosage and results of self monitoring of blood glucose(SMBG)from baseline to endpoint(24 weeks)were evaluated.

 Regarding HbA1C,casual blood glucose and body weight,there were no statistically significant changes after 24 weeks of treatment with biphasic insulin aspart 30. Total daily insulin dose significantly increased from baseline to endpoint(p<0.0005). In 5 patients in whom SMBG data were available,averages of blood glucose level before breakfast and dinner were significantly improved. Frequency of minor hypoglycemic episodes did not increase during the treatment period.

 In conclusion,twice daily biphasic insulin aspart 30 had comparable efficacy and safety switching from biphasic human insulin 40R or 50R. Therefore,twice daily biphasic insulin aspart 30 can be considered as an alternative treatment in Type 2 diabetic patients treated with biphasic human insulin 40R or 50R,because biphasic insulin aspart 30 has the advantage of meal time dosing.


Copyright © 2006, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1347-8389 印刷版ISSN 1347-8176 医学書院

関連文献

もっと見る

文献を共有